BetterLife Pharma Inc (NPAU) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BetterLife Pharma Inc (NPAU) has a cash flow conversion efficiency ratio of 0.030x as of July 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-172.31K ≈ $-201.45K USD) by net assets (€-5.81 Million ≈ $-6.79 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is BetterLife Pharma Inc worth for the company's overall valuation and market capitalisation.
BetterLife Pharma Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how BetterLife Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
BetterLife Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BetterLife Pharma Inc ranked by their cash flow conversion efficiency. Explore BetterLife Pharma Inc (NPAU) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cyabra, Inc. Common Stock
NASDAQ:CYAB
|
0.200x |
|
Questor Technology Inc.
V:QST
|
-0.015x |
|
Elite Education Group International Ltd
NASDAQ:EEIQ
|
-0.327x |
|
LEHNER INVESTMENTS AG
F:LEH
|
N/A |
|
USWE Sports AB
ST:USWE
|
-0.007x |
|
Adalta Ltd
AU:1AD
|
2.240x |
|
TruCap Finance Limited
NSE:TRU
|
1.175x |
|
Avada Group Ltd
AU:AVD
|
-0.227x |
Annual Cash Flow Conversion Efficiency for BetterLife Pharma Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of BetterLife Pharma Inc from 2017 to 2025. View BetterLife Pharma Inc (NPAU) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-01-31 | €-7.36 Million ≈ $-8.61 Million |
€-2.02 Million ≈ $-2.36 Million |
0.275x | -14.52% |
| 2024-01-31 | €-7.70 Million ≈ $-9.00 Million |
€-2.47 Million ≈ $-2.89 Million |
0.321x | +60.97% |
| 2023-01-31 | €-7.53 Million ≈ $-8.81 Million |
€-1.50 Million ≈ $-1.76 Million |
0.200x | -93.09% |
| 2022-01-31 | €-3.88 Million ≈ $-4.54 Million |
€-11.20 Million ≈ $-13.10 Million |
2.887x | +85.82% |
| 2021-01-31 | €-4.61 Million ≈ $-5.39 Million |
€-7.16 Million ≈ $-8.38 Million |
1.553x | +152.37% |
| 2020-01-31 | €2.66 Million ≈ $3.11 Million |
€-7.88 Million ≈ $-9.21 Million |
-2.966x | -121.11% |
| 2019-01-31 | €3.51 Million ≈ $4.10 Million |
€-4.71 Million ≈ $-5.50 Million |
-1.342x | -113.38% |
| 2018-01-31 | €-55.99K ≈ $-65.46K |
€-561.52K ≈ $-656.48K |
10.029x | +5290.49% |
| 2017-01-31 | €-1.93 Million ≈ $-2.26 Million |
€-359.45K ≈ $-420.23K |
0.186x | -- |
About BetterLife Pharma Inc
BetterLife Pharma Inc., a biotechnology company, primarily focuses on developing compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight viral infections. The company's products pipeline includes BETR-001 for the t… Read more